Chemometec — Januar 2023
-
Opjustering p.t. er noget optimistisk - ikke mindst i betragtning af problemerne med at kunne producere det nye håb Xytomatic. Afklaring heraf står øverst på min ønskeseddel. Umiddelbart tror jeg, at aktien går en længere kedelig udvikling imøde. Og nej, jeg tror ikke på, at casen er i top p.t.
-
Ikke jeg har set - seneste jeg har læst, var, at de forventede det løst i Q1 med leveringerne - men at de først forventede begyndende bredt salg i Q2. Tager gerne fejl

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind